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1. Introduction  
Organ transplantation is now the treatment of choice for many end-stage diseases. 
However, the gap between organ demand and donor availability has progressively 
widened, and the severe shortage of organs for transplantation has resulted in the increasing 
use of expanded donor criteria, allowing the inclusion of older donors as well as donors 
with mild disease. Thus, organ donation may involve the risk of the transmittal of unwanted 
host factors, such as infections and malignancies. Infectious microbes and unexpected 
diseases that are present in an organ donor have the potential to be transmitted to the 
transplant recipient. Although the transmission of donor-derived infectious diseases was 
reported to occur in less than 1% of all donations from deceased donors, significant 
morbidity and mortality can occur following such disease transmissions. Infectious diseases 
remain a major complication in solid organ transplantation, and the study of donor-derived 
infections is an evolving field. Despite recent improvements in the microbiological screening 
of donors and detailed reviews of potential donors’ medical records, persistent clusters of 
donor-derived infections in transplant recipients remain. Bacterial, viral, fungal, parasitic, 
and other rare infections can be transmitted through organs and tissue allografts. However, 
the transmission of microorganisms from allografts is not likely to cause infectious 
complications in every transplant recipient. The risk of infection is mostly related to the 
recipient’s net state of immunosuppression. The balance between the recipient’s state of 
immunosuppression and epidemiological exposures contribute to the risk of infection 
(Fishman, 2007; Fishman & Rubin, 1998). Immunosuppression not only increases the risk of 
tissue invasion, dissemination, and superinfection, but also blunts the typical inflammatory 
responses that alert clinicians to the presence of infection after exposure. As a result, the 
recognition of infection is more difficult in transplant recipients than in individuals with 
normal immunities. The presentations of infections are often complicated by noninfectious 
events, such as allograft rejection. Specifically, 40% of infections in liver transplant recipients 
were not associated with fever (Chang et al., 1998). Thus, intervention treatments of 
infections may be delayed. The goals of patient care after organ transplantation are to 
prevent the transmission of donor-derived infections, to recognize the presence of infections 
in solid-organ transplant recipients, and to intervene early when such infections occur. In 
addition, malignancies that are transmitted from the donor due to direct transmission of 
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tumors or to tumors arising in cells of donor origin can also occur in organ transplantation. 
For example, melanoma, which is one of the most frequently reported and lethal donor-
derived malignancies, has a high transmission rate. Therefore, potential organ donors 
should be carefully screened for histories of malignancies. 
2. Potential infections of the donor 
Potential infections acquired from a donor can be classified into two categories: infections 
that already existed in the patient prior to becoming a potential donor and nosocomial 
exposures of the donor after hospitalization. Preexisting infections may be present in either 
living or deceased donors, and the majority of such infections are viral. Some of these 
infections, which might be detected by donor and recipient screening, involve infection from 
a seropositive donor to a seronegative recipient, including the transmission of 
cytomegalovirus (CMV), Epstein-Barr virus (EBV), or toxoplasmosis, while others are 
unexpected despite routine donor screening. Unexpected clusters of donor-derived viral 
infections in transplant recipients have occurred, including rabies, West Nile virus (WNV), 
Human immunodeficiency virus (HIV), herpes simplex virus, hepatitis B virus (HBV), and 
hepatitis C virus (HCV) (Morris et al., 2010). Nosocomial donor infections are most 
commonly related to bacterial pathogens. These infections are usually caused by the same 
nosocomial pathogens that infect other patients with similar lengths of stay in the intensive 
care unit. Wu and colleagues have shown that several factors, including a longer stay in an 
intensive care unit, previous cardiopulmonary cerebral resuscitation, and the use of 
inotropic agents, contribute to the risk of infection of a potential donor (Wu et al., 2008). 
Additionally, infected donors may also transmit microorganisms that are resistant to formal 
antimicrobial treatments. The use of organs from deceased donors with potential infections 
is controversial, and there is a need for improved microbiological screening tools and 
therapies.  
Opportunistic infections are generally uncommon in the first 1–4 weeks after transplantation 
because the impact of immunosuppression depends on prolonged exposure to suppressive 
therapies. Unexplained early infections in this period are generally donor-derived or 
associated with surgery-related complications. Thus, a thorough investigation of infectious 
diseases in a potential donor is mandatory. The implementation of a preventive strategy of 
universal prophylaxis that provides antimicrobial therapy to all at-risk potential donors may 
alter the incidence and severity of organism transmission as well as post-transplant 
infections. However, routine antimicrobial prophylaxis should be adjusted based on the 
organ transplanted, individual exposures, and hospital epidemiology. Prophylaxis can also 
be adjusted according to known colonization patterns. All active infections in the donor 
should be eradicated or controlled prior to transplantation, as these may be transmitted and 
reactivated in the transplant recipient, which may lead to significant morbidity and 
mortality.  
3. Screening of the risks of infections of organ donors 
Benjamin Franklin said that an ounce of prevention is worth a pound of cure. The 
pretransplantation screening of potential organ donors is essential for the prevention of 
disease transmission, as well as the success of solid organ transplantation. Pretransplantation 
infectious disease screenings of potential donors are helpful in: (1) identifying conditions  
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that may disqualify the donor, (2) identifying and treating active infections prior to 
transplantation, (3) identifying the risk of infection and determining strategies for 
preventing and mitigating infection after transplantation, and (4) implementing preventive 
interventions, such as updating the recipient’s vaccination status. Although there is general 
consensus on the major infections for which screening should be performed, there is some 
variation in the types of screening used in different transplantation centers. A number of 
publications have discussed guidelines for the pretransplant screening of organ donors 
(Avery, 2004; Delmonico & Snydman, 1998; Fischer & Avery, 2009). Some documented 
infections preclude organ donation under specific infectious conditions, including 
uncontrolled sepsis, HIV or human T-cell lymphotropic virus (HTLV) infection, rabies, 
WNV infection, and lymphocytic choriomeningitis virus (LCMV) infection. Therefore, organ 
donors should be screened for the risk of infection on the basis of organ-procurement 
standards. The screening should include the donor’s medical history as well as laboratory 
serologic testing.  
3.1 Screening the donor’s medical/behavioral history 
A thorough medical history and physical examination are the first steps in donor screening. 
An accurate medical and social history, as well as the donor’s recent and remote exposures, 
is important in the assessment of donor eligibility. This initial evaluation may address 
current or active infections prior to organ procurement. Each potential donor should be 
screened for medical conditions that may affect the function of the donated organ, for the 
presence of transmissible disease or malignancies that are treated or untreated, or for any 
other known condition that may be transmitted by the donor organ that may reasonably 
affect the recipient. This history should also be used to identify whether the potential donor 
has factors associated with an increased risk of transmission of infection, including the 
blood-borne pathogens HIV, HBV, and HCV. The data that should be collected when 
assessing donor eligibility are summarized in Table 1.  
 
Medical history 
Previous infection  
Vaccinations 
Occupational exposures  
Travel history 
History of transfusions with blood or blood products 
Any contact with people with human immunodeficiency virus (HIV), hepatitis B 
virus (HBV), hepatitis C virus (HCV), or other transmissible diseases 
Tattooing, ear or body piercing 
Use of illicit drugs 
Sexual behavior 
Incarceration 
Contact with animals, including pets, bats, stray dogs, or rodents 
Physical examination 
Table 1. Suggested data to be collected for determining eligibility prior to organ donation 
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However, due to the limited pool of donors, it has become increasingly important to 
consider marginal donors, including those with infections at the time of donation. The 
decision to use organs from an infected donor reflects the urgency of transplantation for the 
recipient and the availability of alternative organs. 
3.1.1 Exclusion of high-risk donors 
The transmission of HIV through liver transplantation has been reported sporadically (Ahn 
& Cohen, 2008; Samuel et al., 1988). The Centers for Disease Control and Prevention of the 
United States (US) has issued guidelines for the classification of donors possessing a high 
risk for HIV infection (CDC, 1994). Potential donors who meet any of the criteria listed 
below should be excluded from the donation of organs or tissues and may be considered 
only if the risk to the recipient of not performing the transplant is deemed greater than the 
risk of HIV transmission and disease. In such a circumstance, it is recommended to inform 
the recipient and discuss the possibility of HIV transmission. 
Behavior/history exclusionary criteria 
1. Men who have had sex with another man in the preceding 5 years. 
2. Persons who report nonmedical intravenous, intramuscular, or subcutaneous injection 
of drugs in the preceding 5 years. 
3. Persons with hemophilia or related clotting disorders who have received human-
derived clotting factor concentrates. 
4. Men and women who have engaged in sex in exchange for money or drugs in the 
preceding 5 years. 
5. Persons who have had sex in the preceding 12 months with any person described in 
items 1-4 above or with a person known or suspected to have HIV infection. 
6. Persons who have been exposed in the preceding 12 months to known or suspected 
HIV-infected blood through percutaneous inoculation or through contact with an open 
wound, non-intact skin, or mucous membrane. 
7. Inmates of correctional systems. (This exclusion is to address issues such as difficulties 
with informed consent and the increased prevalence of HIV in this population.) 
Specific exclusionary criteria for pediatric donors 
• Children meeting any of the exclusionary criteria listed above for adults should not be 
accepted as donors. 
• Children born to mothers with HIV infections or mothers who meet the behavioral or 
laboratory exclusionary criteria for adult donors (regardless of their HIV status) should 
not be accepted as donors unless HIV infection can be definitely excluded in the child as 
follows: 
• Children greater than 18 months of age who are born to mothers with, or at risk for, 
HIV infection, who have not been breast fed within the last 12 months, and whose 
HIV antibody tests, physical examination, and review of medical records do not 
indicate evidence of HIV infection can be accepted as donors. 
• However, children less than or equal to 18 months of age who are born to mothers 
with, or at risk for, HIV infection should not be accepted as donors regardless of 
their HIV test results. 
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3.2 Laboratory screening tests 
In the US, all laboratory testing of donors must be performed in an appropriately accredited 
laboratory utilizing nationally licensed, approved, or cleared serological screening tests. 
Laboratory screening of potential donors is generally performed for HIV, HBV, HCV, and 
syphilis. The serological tests most frequently used for donor screening are listed in Table 2.  
 
Human immunodeficiency virus (HIV) antibody 
Hepatitis B (HBV) serologic tests: 
HBV surface antigen (HBsAg) 
HBV core antibody (HBcAb IgM and IgG) 
HBV surface antibody (HBsAb) 
Hepatitis C (HCV) antibody  
Venereal Disease Research Laboratory (VDRL) test or Rapid Plasma Reagin (RPR) 
Cytomegalovirus (CMV) antibody IgM and IgG 
Epstein-Barr virus (EBV) antibody panel  
Herpes simplex virus antibody 
Varicella-Zoster virus antibody 
Human T cell lymphotrophic virus (HTLV-I/II) antibody (for donors originating from 
high-incidence areas) 
Toxoplasma antibody (optional, not routinely performed for noncardiac donors) 
Blood and urine cultures 
Table 2. Common screening tests for potential organ donors 
Serology for HTLV-I/II is routinely performed in the US, but in Europe and other areas, this 
assay is restricted to donors living in, or originating from, high-incidence areas. However, 
the risk of infection may be difficult to assess, especially if HTLV has been transmitted 
vertically or sexually. Toxoplasmosis is a major concern, particularly in heart 
transplantation, but it is rarely transmitted to liver recipients (Mayes et al., 1995). Thus, 
toxoplasmosis screening is not routinely performed for noncardiac donors. Donor screening 
for toxoplasmosis is also not advocated based on the small amount of information gained 
and the high rate of false-positive results. In addition, a seropositive result for toxoplasma 
does not contraindicate organ donation, but does provide information that determines 
appropriate prophylaxis and treatment options following transplantation.  
3.2.1 Donors with identified infections 
The use of organs from deceased donors who had fevers or viral infections remains 
controversial, indicating the need for improved microbiological screening tests. However, 
the urgent demand for organs has led to the use of organs from donors with identified 
infections for specific recipients based on the urgency of the need for transplantation and the 
availability of antimicrobial therapies. Ideally, all active bacterial or fungal infections in the 
donor should be treated and resolved prior to transplantation. Currently, no 
recommendations are available regarding the optimal duration of therapy before 
transplantation or the interval required between resolution of the infection and 
transplantation. It may not be possible to document clearance of the infection in an 
emergent situation of life-saving transplantation. Common infections in donors that have 
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been treated adequately should not preclude the use of organs, and decisions must be 
flexible and individualized to the recipient.  
Additionally, livers from donors with HBV infection (HBcAb- or HBsAg-positive) may be 
used in recipients who have previously been infected or are in life-threatening situations, 
with appropriate treatment with specific anti-HBV antiviral agents (Seehofer & Berg, 2005; 
Trautwein, 2004). Similarly, the use of HCV-infected organs is generally reserved for HCV-
infected recipients or for selected HCV-negative recipients (Ghobrial et al., 2001; Vargas et 
al., 1999; Velidedeoglu et al., 2002). Suggested organ donation strategies that are based on 
donor screening data are summarized in Table 3 (Grossi & Fishman, 2009).  
 
Serologic finding Action 
Antibody to human 
immunodeficiency virus (HIV) 
Exclude from organ donation 
Antibody to human T-cell 
lymphotropic virus (HTLV) I/II 
Generally exclude from organ donation (may be used 
in life-threatening situations with informed consent) 
Antibody to hepatitis C virus 
(HCV) 
If used, organs are usually reserved for recipients 
with antibodies to HCV or severely ill recipients 
Antibody to cytomegalovirus 
(CMV) 
Use information to determine prophylaxis (in 
conjunction with recipient serology) 
Antibody to Epstein-Barr virus 
(EBV) 
Consider PCR monitoring if donor is seropositive 
and recipient is seronegative 
Hepatitis B virus (HBV) surface 
antigen (HBsAg) + or HBV core 
antibody (HBcAb IgM) +  
Exclude from organ donation (possible use in life-
threatening situations with intensive prophylaxis) 
HBV surface antibody (HBsAb) + Generally safe for organ donation 
HBV core antibody (HBcAb) IgG 
+ 
High-risk for transmission if liver is used for 
donation, but used at some centers with intensive 
prophylaxis; nonhepatic organs carry a small risk of 
transmission of HBV and are used for vaccinated 
recipients or with prophylaxis  
Rapid Plasma Reagin (RPR) + Not a contraindication to donation. Recipient should 
receive benzathine penicillin 
Antibody to Toxoplasma Not a contraindication to donation. Sulfa-allergic, 
seronegative heart transplant recipients with a 
seropositive donor should receive pyrimethamine 
prophylaxis 
Table 3. Suggested strategies based on donor screening results 
3.3 Additional considerations for donor screening  
Despite the use of highly sensitive assays and the development of new policies, the 
transmission of infections to organ transplant recipients remains uncommon. However, it 
does occur with sufficient frequency to suggest that the current approaches to donor 
screening are inadequate. Many potential exposures are too nonspecific to allow appropriate 
decision-making regarding the risk of transmission.  
www.intechopen.com
 
Donor-Derived Infectious Complications and Disease Transmission 
 
417 
3.3.1 Hemodilution of donor blood samples 
All blood samples obtained and used for screening tests must be assessed for hemodilution, 
which is defined as the dilution of plasma that is sufficient to affect the results of 
communicable disease testing. Blood samples from a deceased organ donor who underwent 
blood loss and transfusion of blood products or infusion of colloids and crystalloids are 
likely to be hemodiluted, which might lead to false-negative test results. The Food and Drug 
Administration (FDA) of the US has published regulations to test specimens from donors 
who have undergone transfusion or infusion (FDA, 2007). Test results from donors who 
have suffered blood loss that was sufficient to require fluid replacement, certain volumes of 
transfusion, and/or infusions should be interpreted with caution. The donor might be 
ineligible unless a pretransfusion sample was available for testing or an appropriate 
algorithm was used to determine if plasma dilution is sufficient to affect test results.  
3.3.2 The window period 
The window period is the time between initial infection and when a test can reliably detect 
that infection, and the poor sensitivity of antibody-based tests within this period increases 
the risk of infection transmission through organ transplantation. As seroconversion may not 
occur during an acute infection, some active infections remain undetectable. For example, 
the period from initial HIV exposure to the development of HIV antibodies is approximately 
22 days, but it can be up to 3–6 months. On average, it takes 2–8 weeks from the time of 
possible exposure for the development of detectable levels of HIV antibodies, leading to 
accurate test results. Therefore, the donor may be seronegative while potentially infected. 
However, recent improvements in the sensitivity of virus-detection assays using nucleic acid 
testing (NAT) have resulted in a significant shortening of the window period (Busch et al., 
2005; Fiebig et al., 2003). The use of NAT may also detect viral replication in HBV core 
antigen (HBcAg)-positive donors who are HBV surface antigen (HBsAg)-negative, in 
addition to reducing the window period of HBV infection (Biswas et al., 2003; Kleinman & 
Busch, 2006). The window period of HCV infection can be reduced by the use of NAT as 
well (Kolk et al., 2002; Schreiber et al., 1996), suggesting the routine use of NAT in the 
screening of potential organ donors for HIV, HBV, and HCV.  
3.3.3 Living donors versus deceased donors 
The screening of living and deceased donors is largely different based on the period during 
which the evaluation is performed. The screening of a prospective living donor is conducted 
at the transplantation center, and the time between screening and transplantation is 
variable. The screening of living donors should include a thorough medical and behavioral 
history, physical examination, laboratory serological tests, radiographic imaging studies, 
and tests for any untreated underlying infectious diseases as needed. Repeat screening tests 
should be considered in the presence of newly developing clinical symptoms and signs in 
living donors between the time of initial screening and transplantation.  
In contrast, the period for deceased donor screening is very short, typically on the order of 
hours. The laboratories associated with organ procurement organizations (OPOs) should 
operate on a 24-hour basis in order to generate the information needed to determine donor 
eligibility (Delmonico & Snydman, 1998; Schaffner, 2001). Because of time constraints,  
www.intechopen.com
 
Liver Transplantation – Technical Issues and Complications 
 
418 
serologic tests are often limited to routinely available and rapid methods. In addition, the 
quality of testing may not be identical in each OPO, and some infections that require more 
sensitive testing may be difficult to detect at an early stage. Therefore, a detailed medical 
history of the potential deceased donor is required to identify potential infections that might 
not be reflected in serologic tests. If a deceased donor with a potential infection risk is to be 
used, the recipient should be informed of the risk of infection transmission. In the future, the 
development of more sensitive and rapid molecular serologic tests may allow immediate 
detection of viral infections, such as HBV, HCV, and HIV.  
4. Transmission of specific pathogens 
A variety of pathogens, including bacteria, fungi, parasites, and viruses, may be transmitted 
through organ transplantation (Table 4) (Gottesdiener, 1989; Ison et al., 2009).  
 
Bacteria Mycobacteria 
Staphylococcus aureus  Mycobacterium tuberculosis 
Klebsiella species Nontuberculous mycobacteria 
Bacteroides fragilis  
Pseudomonas aeruginosa Parasites/Protozoa 
Escherichia coli Toxoplasma gondii 
Salmonella species Strongyloides stercoralis 
Yersinia enterocolitica Plasmodium species 
Treponema pallidum Trypanosoma cruzi 
Brucella species  
Bartonella species Viruses 
Enterobacter species Cytomegalovirus 
Acinetobacter species Epstein-Barr virus 
 Herpes simplex virus 
Fungi Varicella-zoster virus 
Aspergillus species Human herpesvirus-6, 7, 8 
Candida species Hepatitis B, C 
Histoplasma capsulatum Human immunodeficiency virus 
Cryptococcus neoformans Human T cell lymphotrophic virus (HTLV) 
Cocciodioides immitis Parvovirus B19 
Scedosporium apiospermum Rabies 
Prototheca species Lymphocytic choriomeningitis virus 
(LCMV) 
 BK virus 
 West Nile virus 
Table 4. Pathogens that are transmitted with solid organ transplantation 
4.1 Bacteria 
Bacteria are the most common cause of infections in liver transplant recipients, with a 
reported incidence of 35–70%. Numerous factors may be associated with recipient infection, 
and bacterial transmission from the donor is one of the possible sources. Deceased donors 
may harbor known or unsuspected bacterial infections, which should be rapidly evaluated 
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by review of medical records, temperature charts, radiography, and cultures when available. 
It is desirable to obtain blood cultures prior to transplantation since occult donor bacteremia 
may occur. If an illness might have involved bacteremia, a thorough investigation should be 
performed to make sure that the target organ has not been infected. Previous studies, 
conducted on a small scale, have documented severely compromised initial allograft 
function when organs from infected donors were used for desperate recipients (Bull et al., 
1995; Nery et al., 1997). Therefore, transplantation programs have been reluctant to use 
organs from donors known to have active bacterial infections. Occasionally, however, a 
bacterial or fungal blood culture taken before organ recovery is reported as positive only 
after life-saving organs have been transplanted into a needy recipient. A retrospective 
review of bacteremic donors has found no evidence that transmitting bacterial infection 
results in poorer outcomes after organ transplantation (Freeman et al., 1999). Moreover, 
organs have been successfully transplanted from donors with bacterial meningitis with no 
evidence of infectious complications in the recipients, who were given appropriate 
antimicrobial therapy (Lopez-Navidad et al., 1997; Satoi et al., 2001). Therefore, potential 
donors with positive blood cultures should not be totally excluded as possible donors. This 
may increase organ availability and help improve the organ shortage.  
4.1.1 Syphilis 
Syphilis is a sexually transmitted infection with a worldwide incidence that is caused by the 
spirochete Treponema pallidum. Although the transmission of syphilis by means other than 
sexual routes is infrequent, it can be transmitted through blood transfusion and organ 
transplantation. Serologic testing of potential organ donors for syphilis is recommended, but 
evidence of syphilis infection is not considered a contraindication to organ donation if 
appropriate prophylactic antibiotics, such as benzathine penicillin, are administered to the 
recipient (Caballero et al., 1998; Ko et al., 1998). Therefore, current guidance suggests that 
organ transplantation from a donor with serologic evidence of a syphilis infection is safe as 
long as there is appropriate treatment of recipients in the posttransplantation phase. 
Recommended regimens of 2–3 doses weekly of 2.4 million units of intramuscular 
benzathine penicillin or an equivalent early syphilis therapeutic regimen should be given as 
soon as possible after transplantation for appropriate prophylaxis and treatment of early 
syphilis acquired from transplantation. 
4.2 Fungi  
Any known active and invasive fungal infection in the potential donor is a contraindication 
to transplantation. However, endemic mycoses may be present in dormant forms and 
transmitted to recipients by organ transplantation. For example, histoplasmosis that was 
transmitted by transplantation has been described, but most cases appeared to involve the 
reactivation of a past infection in the recipient (Limaye et al., 2000). Nonetheless, 
radiographic signs of suspected previous histoplasmosis have not been considered a 
contraindication to donation, and a consensus regarding recommendations for donor 
screening for endemic mycoses has not emerged yet.  
4.2.1 Candida species 
The incidence of fungal infections in liver transplant recipients is higher than in recipients of 
other types of solid organ transplants. The reasons for this high rate of fungal infection are  
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not completely understood, but specific risk factors, including retransplantation, prolonged 
or repeat surgeries, high transfusion requirements, renal failure, fungal colonization, and 
predisposition to fungal infections in liver transplant recipients, have been identified 
(Castaldo et al., 1991; Collins et al., 1994). The incidence of invasive fungal infections 
following liver transplantation ranges between 14% and 42%, and these infections are 
associated with high overall mortality rates (Briegel et al., 1995; Paya, 2002). Most fungal 
infections generally occur within the first 3 months following liver transplantation and are 
viewed as classic nosocomial infections instead of donor-derived transmissions. Infections 
due to Candida species are the most common invasive fungal infections among solid organ 
transplant recipients, accounting for over half of all fungal infections. However, the 
occurrence of invasive candidiasis, especially among liver and small bowel transplant 
recipients, is often substantially higher.  
The diagnosis of invasive candidiasis is dependent on the recovery of the organism from a 
sterile body site, such as the bloodstream, intraabdominal fluid, pleural fluid, or abscess 
material. Unfortunately, cultures, especially blood cultures, are not sensitive enough to 
identify patients with invasive candidiasis. Even with newer blood culture techniques, the 
overall sensitivity of blood cultures for identifying Candida species is estimated to be 70% 
(Berenguer et al., 1993). Thus, the development of nonculture-based diagnostic 
methodologies is especially important. Presently, the 1-3, beta-d-glucan assay is probably 
the most reliable, with a sensitivity and specificity of 70% and 87%, respectively, among 
patients who have proven invasive candidiasis (Obayashi et al., 2008; Ostrosky-Zeichner et 
al., 2005). The treatment of invasive candidiasis in organ transplant recipients, which is 
similar to treatment in most other patients, is based on updated clinical practice guidelines 
for the management of candidiasis (Pappas et al., 2009).  
4.2.2 Aspergillus species 
Aspergillosis accounts for 1–9.2% of invasive fungal infections in liver transplant recipients 
(Brown et al., 1996; Gavalda et al., 2005; Kusne et al., 1992). It is similar to other fungal 
infections in that aspergillosis is likely to be a nosocomial infection after transplantation and 
not due to donor-derived transmission. A number of well-characterized risk factors have 
been shown to portend a high risk of invasive aspergillosis following liver transplantation, 
of which retransplantation and renal failure are among the most significant (Fortun et al., 
2002; Gavalda et al., 2005; Singh et al., 2001). Historically, invasive aspergillosis in liver 
transplant recipients has predominantly occurred in the early posttransplant period. The 
mortality rate of liver transplant recipients with invasive aspergillosis has ranged from  
83–88% (Denning, 1996; Singh et al., 1997; Singh et al., 2006), highlighting the need for 
aggressive diagnostic evaluation and treatment. A substantial delay in establishing an early 
diagnosis remains a major impediment to the successful treatment of invasive aspergillosis. 
Cultures of respiratory tract secretions are less sensitive, and fungus may only be detected 
in clinical samples from the late stages of the disease. However, a positive culture of 
Aspergillus from respiratory tract samples does not always indicate invasive disease, and 
the significance of a positive culture from an airway sample also varies with the type of 
organ transplant. 
The utility of the galactomannan test for the early diagnosis of invasive aspergillosis has 
been assessed in solid organ transplant recipients. However, false-positive galactomannan 
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tests have been documented in up to 13% of liver transplant recipients (Kwak et al., 2004), 
but the sensitivity of the assay for the diagnosis of invasive aspergillosis may be improved 
by testing bronchoalveolar lavage (Husain et al., 2007). The diagnosis of invasive 
aspergillosis using the 1-3, beta-d-glucan assay has not been fully defined, but one study has 
shown that the test was useful for the diagnosis of invasive aspergillosis in living-donor 
liver transplant recipients (Kawagishi et al., 2006).  
Currently, prophylaxis against invasive aspergillosis is not routinely recommended in all 
solid organ transplant recipients. A more rational approach is to provide antifungal 
prophylaxis to high-risk liver transplant recipients (Singh & Husain, 2009). The treatment of 
invasive aspergillosis in liver transplant recipients remains generally the same as in other 
patients. Prompt initiation of antifungal therapy is crucial for achieving optimal outcomes in 
recipients with invasive aspergillosis. Because of their lower potential of nephrotoxicity, 
lipid formulations of amphotericin B have been the mainstay for the treatment of invasive 
aspergillosis in solid organ transplantation since the early 1990s. The availability of newer 
triazole agents and echinocandins that have potent anti-Aspergillus activity and better 
tolerability profiles have led to an expanded arsenal of antifungal agents for the treatment of 
invasive aspergillosis. Voriconazole is now regarded as the drug of choice for the primary 
treatment of invasive aspergillosis in all hosts, including solid organ transplant recipients, 
based on the clinical guidelines of the Infectious Diseases Society of America (IDSA) for the 
treatment of invasive aspergillosis (Walsh et al., 2008). For the primary treatment of invasive 
pulmonary aspergillosis, intravenous or oral voriconazole is recommended for most 
patients, while the parenteral formulation is recommended for seriously ill patients. In 
patients developing toxicity to or with contraindications against voriconazole, liposomal 
amphotericin B is considered an alternative primary therapy according to the IDSA 
guidelines, but higher doses are not recommended. Amphotericin B lipid complex, 
itraconazole, caspofungin, posaconazole, or micafungin are other rational choices for 
alternative therapies for invasive aspergillosis (Walsh et al., 2008).  
Currently, caspofungin, which is the only echinocandin approved by the FDA for the 
treatment of invasive aspergillosis, has been used successfully as a single agent or in 
combination with other drugs for salvage therapy in invasive aspergillosis (Carby et al., 
2004; Forestier et al., 2005). However, the efficacy of combination antifungal therapy for 
invasive aspergillosis has not been fully defined. Thus, the routine administration of a 
combination regimen for primary therapy is not recommended. In the context of salvage 
therapy, an additional antifungal agent may be added to existing therapy, or combination 
antifungal drugs from different classes other than those in the initial regimen may be used 
(Walsh et al., 2008).  
4.2.3 Cryptococcus species 
Cryptococcosis, which is the third most common invasive fungal infection, accounts for 
approximately 8% of the invasive fungal infections in solid organ transplant recipients. The 
overall incidence of cryptococcal disease in solid organ transplant recipients ranges from 
0.3–5% (Singh & Forrest, 2009). As in most other hosts, cryptococcal disease in solid organ 
transplant recipients is considered a reactivation of a quiescent infection. However, rare 
cases of transmission from donor organ and tissue grafts have also been reported (Beyt & 
Waltman, 1978; Kanj et al., 1996; Ooi et al., 1971). Approximately 53–72% of solid organ  
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transplant recipients with cryptococcosis develop disseminated disease or central nervous 
system (CNS) involvement. Among solid organ transplant recipients, liver transplant 
recipients had a 6-fold higher risk for developing disseminated disease than recipients of 
other types of transplants. The overall mortality of solid organ transplant recipients with 
cryptococcosis in the current era is 14%, but it may be higher in those with CNS 
involvement (Singh et al., 2007).  
All patients with suspected cryptococcosis should undergo complete evaluations, including 
lumbar punctures, blood and urine cultures, chest X-rays, or bronchoalveolar lavages with 
biopsies when necessary, in order to determine the extent of the disease, as this will dictate 
management. Distinguishing between disseminated disease and localized pulmonary and 
asymptomatic disease is necessary prior to initiating therapy. In patients with neurologic 
and disseminated disease or severe pulmonary disease, the recommended treatment 
includes induction therapy with an amphotericin B product and flucytosine, followed by 
consolidation with fluconazole, and, finally, maintenance with fluconazole (200–400 
mg/day) for 6–12 months in order to complete the regimen. The recommended treatment 
for focal or incidentally detected pulmonary disease in otherwise asymptomatic patients is 
fluconazole (400 mg/day) for 6–12 months (Dromer et al., 2008; Saag et al., 2000). Currently, 
the use of extended-spectrum azoles, such as voriconazole, itraconazole, and posaconazole, 
have not shown any extra benefits over fluconazole (Singh & Forrest, 2009).  
4.3 Mycobacteria  
Mycobacterium tuberculosis (TB) is a serious opportunistic infection that may affect transplant 
recipients. The prevalence of active TB among solid organ transplant recipients is estimated 
to be 1.2–6.4% in most countries, and it has been reported to be up to 15% in highly endemic 
areas. The mortality rate in these populations is close to 30% (Munoz et al., 2005). The 
incidence of active TB in adult liver transplant recipients has been reported to be 0.47–2.3% 
(Munoz et al., 2005; Torre-Cisneros et al., 2009). The most frequent mode of acquisition is 
thought to be reactivation of dormant disease; however, transmission with an allograft has 
been documented to occur in liver transplant recipients (Aguado et al., 2009; Kiuchi et al., 
1997). Because of this risk, all potential living donors should be given a thorough history, 
documenting TB risk factors, exposures, and infections, and undergo a tuberculin skin test 
(TST) or interferon-γ release assay. If either test is positive, additional testing and a 
symptom review should be performed in order to rule out active infection. Prospective 
living donors with active TB should not be considered for transplantation, and those with 
latent TB infection should be given treatment (with isoniazid for 9 months or rifampin for 4 
months) prior to transplantation. However, one study demonstrated no benefit to treating 
prospective living donors with latent TB infections prior to transplantation (Hernandez-
Hernandez et al., 2006). The optimal length of therapy prior to liver donations remains 
unclear, and a shorter course of therapy might be feasible with the caveat that the recipients 
will be treated after liver transplantation. In the case of deceased donors, it is not possible to 
perform TSTs, but a history of previously active TB and any associated treatment should be 
obtained from the donor’s family or relatives. Organs from potential donors, whether living 
or deceased, with active TB or a high suspicion of active TB should not be used. Recipients 
of organs from donors with latent TB should consider preventive therapy with isoniazid for 
up to 9 months (Yehia & Blumberg, 2010).  
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The initiation of posttransplant preventive treatment should begin as soon as medically 
possible after the recipient is stabilized in order to prevent the development of reactivated 
diseases. Once therapy is started, transplant recipients should be routinely monitored for 
drug-related hepatotoxicity. A suggested approach is to monitor liver enzymes at 2-week 
intervals for 6 weeks and then monthly. If significant hepatotoxicity is observed, alternative 
regimens, such as ethambutol plus either levofloxacin or moxifloxacin, could be considered 
for high-risk individuals (Aguado et al., 2009). If no alternative treatment is possible, then 
careful clinical follow-up with prompt diagnostic attention to pulmonary symptoms is likely 
the best strategy.  
The standard treatment recommendation for active TB in the general population is to 
administer a 4-drug regimen of isoniazid, rifampin, pyrazinamide, and ethambutol for a 2-
month intensive phase, followed by a continuation phase of 4–7 months (Blumberg et al., 
2003). Other agents used in the treatment of TB are aminoglycosides and fluoroquinolones, 
which are primarily used in cases of multidrug resistance or intolerance of first-line 
medications. Treatment of active TB in liver transplant recipients should consider the 
known risks of drug-related hepatotoxicity and drug-drug interactions between 
antituberculosis medications and immunosuppressive agents. These considerations also 
have an impact on the suggested length of treatment. The ideal length of TB therapy in liver 
transplant recipients remains controversial, and it is affected by the extent of the disease, 
choice of regimen, response to therapy, and resistance profile of the organism.  
4.4 Protozoa/parasites 
Parasitic diseases may affect transplant recipients as a result of natural infection, 
recrudescence of a previous latent infection in the recipient, or transmission by organ 
transplantation. For the most part, only those organisms that can complete their life cycle 
within the human host lead to more severe infections in an immunocompromised host. The 
incidence of parasitic infection is expected to increase in solid organ transplant recipients 
due to the universal expansion of transplantation programs, and the increase in the numbers 
of donors or recipients who are originally from endemic areas but are currently spreading 
throughout the world.  
4.4.1 Toxoplasma gondii 
Toxoplasma gondii infection in transplant recipients can be caused by a primary infection 
transmitted by an allograft. Although recipients of heart transplantation have the highest 
incidence of this disease among solid organ transplant recipients, toxoplasmosis has been 
described in liver transplant recipients as well. Transplant recipients with active 
toxoplasmosis may present with brain abscess, chorioretinitis, pneumonitis, or disseminated 
disease. The diagnosis of toxoplasmosis requires the identification of tachyzoites in biopsy 
samples or clear seroconversion. The presence of multiple ring-enhancing lesions in a CNS 
imaging study, especially with the coexistence of anti-toxoplasma IgG antibodies, is 
suggestive of CNS toxoplasmosis and is sufficient to start presumptive treatment for CNS 
toxoplasmosis. Optimal treatment after solid organ transplantation has not been well-
defined. The recommendations of treatment for active toxoplasmosis generally includes a 
prolonged course (4–6 weeks or longer) of pyrimethamine and sulfadiazine with folinic 
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acid, followed by suppressive therapy, or trimethoprim-sulfamethoxazole treatment, 
followed by suppressive therapy (Kotton & Lattes, 2009).  
4.4.2 Trypanosoma cruzi 
Chagas disease, caused by the flagellate protozoan parasite Trypanosoma cruzi, has been 
transmitted by unscreened blood transfusion, from infected mother to fetus, by laboratory 
accidents, or even by organ transplantation (de Faria & Alves, 1993; Vazquez et al., 1993). 
Routine screening for Trypanosoma cruzi prior to transplantation is not yet mandatory. In 
countries where the disease is endemic, transplant teams do accept organs from infected 
donors provided no better donor is available in a reasonable life-saving situation and with 
informed consent. Diagnosis can be achieved by direct parasitological tests, including the 
examination of whole blood preparations, by a concentration method (Strout test) (Strout, 
1962) in the acute phase, and by serological tests in the intermediate and chronic stages. Two 
drugs, nifurtimox and benznidazole, are available for treatment. Parasitic cure is achieved in 
60–100% of acute cases when either drug is administered for 30–60 days (Bern et al., 2007).  
4.4.3 Strongyloides stercoralis 
Strongyloides stercoralis is endemic in tropical and subtropical regions. Strongyloidiasis, 
which has mainly been described in kidney transplant recipients, has been considered in 
most cases to be caused by reactivation of a latent infection (Hoy et al., 1981). More recently, 
a few cases have been documented in pancreatic and intestine transplant recipients and 
were attributed to transmission from the donated organs (Ben-Youssef et al., 2005; Patel et 
al., 2008). The clinical disease may present with pulmonary involvement, sepsis, meningitis 
with multiple gram-negative rods, and acute and severe abdominal disease, including ileus 
and intestinal obstruction, and gastrointestinal hemorrhage. These symptoms are caused by 
the damage inflicted by larvae that penetrate through the intestinal wall. A definitive 
diagnosis is based on the identification of larvae in clinical specimens, mainly in stool and 
duodenal aspirate. All recipients with confirmed diagnoses should be treated with 
ivermectin or albendazole. Thiabendazole is another agent that has been extensively used 
clinically, but it is probably the least satisfactory of all available drugs because of its high 
relapse rates and toxicities (Liu & Weller, 1993). Strongyloidiasis can be a devastating 
disease in transplant recipients despite therapy. The mortality rate approaches 50–70% in 
recipients with hyperinfection syndrome and disseminated infection (Patel et al., 2008).  
4.5 Viruses 
Solid organ transplant recipients are uniquely predisposed to develop severe clinical 
illnesses related to a variety of common and opportunistic viruses. Transplant recipients 
may acquire viral infections from the donor (donor-derived transmission), from reactivation 
of endogenous latent infection, or from the community. Herpes viruses, most notably CMV 
and EBV, are the most common opportunistic viral pathogens that cause infection after solid 
organ transplantation. HBV and HCV are unique challenges, particularly among liver 
transplant recipients. Infection by polyoma BK virus is an important cause of allograft 
dysfunction in kidney transplant recipients, but viremia is relatively uncommon in liver 
transplant recipients. Other less common viral infections, including adenoviruses, 
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parvovirus B19, and WNV, may affect liver transplant recipients as well. Treatment of virus 
infections with proven effective antiviral drug therapies should be weighed against the 
potential reduction of immunosuppression. For viruses without proven effective therapies, 
reduction in the degree of immunosuppression remains the sole effective strategy for 
management. Therefore, the prevention of viral infections is of the utmost importance, and 
this may be accomplished by pretransplant screening of the donor and recipient to 
determine prophylactic and preventive strategies to be utilized after transplantation or 
posttransplant vaccinations and effective antiviral treatments. 
4.5.1 Cytomegalovirus 
Cytomegalovirus (CMV) infections, which have been recognized in every human population, 
are widely distributed in the general population with seroprevalence ranging from 30–97% 
(Humar & Snydman, 2009; Paya, 2001). The patterns of CMV acquisition vary greatly based 
on geographic and socioeconomic backgrounds of each population, and seroprevalence 
increases generally with age. Importantly, CMV infection is a major cause of morbidity in 
patients receiving solid organ transplants. CMV disease usually occurs 1–4 months after 
liver transplantation, and those recipients who are seronegative for CMV and receive an 
allograft from a seropositive donor are at highest risk. Other risk factors for CMV disease 
include the recipient’s overall state of immunosuppression (e.g., type of drug, dose, timing, 
duration) and various host factors (e.g., age, comorbidity, neutropenia). The risk of CMV 
disease also varies with the type of transplant. This may be due to the degree of 
immunosuppression or the viral load present in the transplanted allograft. The lowest risk 
of disease occurs when both donor and recipient are seronegative for CMV. Thus, 
pretransplant CMV screening of donors and recipients should be performed to allow for risk 
stratification.  
The diagnosis of CMV infection and disease has evolved considerably. Historically, the 
histological detection of owl's eye inclusion bodies has been used for the diagnosis of CMV 
disease. However, this method is limited by its invasive approach and insensitivity for 
detecting CMV organ involvement. For years, culture-based methods, such as shell-vial 
centrifugation detection or culture of the organism from clinical specimens, were used for 
CMV diagnosis. However, tissue culture can take weeks and the shell-vial centrifugation 
assay is insensitive compared with molecular assays. Newer methods for diagnosing CMV 
disease include detection of the pp65 antigen and a molecular diagnostic test; both methods 
are performed on serum and are rapid, with reasonable sensitivity and specificity. The pp65 
antigen assay is a semiquantitative fluorescent assay that is based on the detection of 
infected cells in peripheral blood. This assay has a far higher sensitivity and specificity than 
culture-based methods (Mazzulli et al., 1999). Molecular diagnostic tests, which may detect 
CMV deoxyribonucleic acid (DNA), can be qualitative or quantitative. Quantitative 
measurements of CMV DNA levels have become popular at many transplantation centers. 
The viral loads measured are associated with the severity of CMV infection (Humar et al., 
1999). Generally, both the pp65 antigen assay and quantitative CMV viral load testing can be 
utilized in preemptive protocols for the diagnosis of CMV infection, as well as to guide the 
management of CMV disease (Caliendo et al., 2000; Emery et al., 2000).  
Currently, two strategies commonly used for CMV prevention include universal 
prophylaxis and preemptive therapy. Universal prophylaxis involves providing antiviral  
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therapy to all at-risk patients beginning in the early posttransplant period for a defined 
duration of 3–6 months. Drugs that have been considered for universal prophylaxis include 
ganciclovir, valganciclovir, acyclovir, valacyclovir, and immunoglobulin preparations (Gane 
et al., 1997; Paya et al., 2004; Snydman et al., 1993). Valganciclovir, which is a valine ester 
prodrug of ganciclovir, has improved bioavailability over the oral form ganciclovir. In 
preemptive therapy, patients are monitored for early evidence of CMV replication at regular 
intervals (often weekly). Patients with early replication are then treated with antiviral 
therapy in order to prevent symptomatic disease. Each approach has advantages and 
disadvantages that must be considered in the context of the patient and the allograft. The 
major concern with CMV prophylaxis continues to be late-onset CMV disease, which is 
defined as disease occurring sometime after discontinuation of antiviral prophylaxis. In 
contrast, preemptive therapy has the potential advantage of targeting therapy to patients at 
highest risk and thereby decreasing drug costs and toxicity.  
No consensus exists regarding the optimal treatment of CMV disease. However, intravenous 
ganciclovir has been used successfully in numerous therapeutic trials to treat solid organ 
transplant recipients with CMV disease and has been considered the mainstay for therapy. 
The basic principle governing CMV treatment is the clearance of viremia. Therefore, patients 
with evidence of CMV viremia should be maintained on therapy until viremia has dropped 
below the negative threshold level for a given test. This helps prevent relapse and the 
development of resistance to ganciclovir. The incidence of ganciclovir-resistant CMV 
remains generally low in most cases after solid organ transplant. In a prospective 
multicenter study, the overall rate of resistance was 1.9% in those who received oral 
ganciclovir versus 0% among those receiving valganciclovir (Boivin et al., 2004). However, 
resistance should be suspected if the patient develops CMV disease after prolonged courses 
of antiviral prophylaxis or the viral load fails to respond to standard ganciclovir treatment. 
Genetic resistance testing may be very helpful in managing resistant CMV. Therapeutic 
options for resistant CMV include reduction or discontinuance of immunosuppression and 
increasing the dosage of intravenous ganciclovir or switching to foscarnet alone or foscarnet 
in combination with low dose ganciclovir. Other unproven or untested therapeutic options, 
including cidofovir, compassionate release maribavir, leflunomide, and artesunate, may be 
considered for refractory cases (Humar & Snydman, 2009).  
4.5.2 Epstein-Barr virus  
EBV is also a herpes virus, and humans are the only known hosts of EBV. This virus has a 
worldwide distribution with seropositive rates of 90% among adults, and its transmission 
depends on the socioeconomic background of the population. In most nonindustrialized 
communities, the vast majority of individuals are EBV-seropositive before the age of 5 years. 
However, in the more developed affluent counties, seropositivity can be delayed until the 
fourth decade of life (Allen, 2005). Although EBV infection may be acquired from the 
community, donor-derived transmission from an EBV-seropositive donor organ is an 
important source of infection among solid organ transplant recipients. EBV is associated 
with the majority of cases of posttransplantation lymphoproliferative disorder (PTLD), 
which is recognized as one of the most devastating complications of organ transplantation. 
The development of PTLD after solid organ transplantation usually occurs in the first year 
after transplantation. Prolonged or extensive immunosuppression and transplantation from 
an EBV-seropositive donor into a seronegative recipient are the two major risk factors for 
www.intechopen.com
 
Donor-Derived Infectious Complications and Disease Transmission 
 
427 
the development of PTLD after solid organ transplantation. CMV infection, which may 
contribute to the net state of immunosuppression, is known to be another risk factor for the 
development of PTLD after transplantation. The incidence of PTLD also varies with the type 
of organ transplantation; the risk for the development of PTLD is highest after small bowel 
transplantation (up to 32%), followed by moderate risk (3–12%) following lung, heart, and 
liver transplantation, and relatively low risk (1–2%) for kidney transplantation (Gottschalk 
et al., 2005). The reasons for these differences are not completely understood, but the 
recipient’s net state of immunosuppression and the amount of lymphoid tissue present in 
the transplanted allografts may be important. 
PTLD may present with a diverse spectrum of nonspecific clinical symptoms and signs that 
involve other organs, including the CNS, bone marrow, kidneys, lungs, small intestine, and 
spleen. Because early diagnosis and treatment may result in better outcome, there is great 
interest in developing tests to predict the development of PTLD. Several investigations have 
indicated that monitoring EBV viral load and analysis of EBV-specific cytotoxic T 
lymphocyte responses may be helpful in assessing the risk of PTLD development in 
recipients (Qu et al., 2000; Rose et al., 2001; Smets et al., 2002). However, tissue biopsies with 
histological classifications remain the current mainstay of PTLD diagnosis.  
The treatment of PTLD remains controversial because of the lack of a unifying consensus 
dictating the specific treatment approaches that should be undertaken for all categories of 
patients. The general approach to therapy involves a stepwise strategy that starts with the 
reduction of immunosuppression; subsequent therapies depend on the clinical situation and 
should be based largely on the clinical response and histopathological characteristics of the 
disease. Additional therapies currently used in clinical practice include antiviral agents, 
intravenous immune globulin, cytokine and anticytokine therapies, surgery or radiation, 
anti-B cell antibodies, and T cell-based cellular immunotherapies (Allen & Preiksaitis, 2009; 
Gottschalk et al., 2005). However, the efficacy of individual therapies is difficult to assess 
because they are often combined. Additional future research is needed to address several 
unresolved issues and to enhance the diagnosis, prevention, and treatment of PTLD.  
4.5.3 Hepatitis B virus  
The transmission of HBV by organ transplantation is hazardous to allograft recipients. The 
acquisition of HBV infection has been associated with rapidly progressive liver disease, 
leading to high rates of liver failure and mortality. Therefore, all prospective donors and 
recipients should be tested for HBV prior to liver transplantation. Although the response to 
vaccination in patients with end-stage organ disease may be suboptimal, it is prudent to 
vaccinate all seronegative transplant candidates with HBV vaccine. Donor screening usually 
includes, at least, HBsAg and HBV core antibody (HBcAb) assays, and it is most useful to 
test for IgG and IgM in the HBcAb assay. HBsAg or HBcAb-IgM positivity usually indicates 
active HBV infection, and HBsAg-negative and HBcAb-IgM-positive individuals may 
represent infection in the window period. A HBsAg-negative and HBcAb-IgG-positive 
result may represent either a false-positive test or persistent HBV infection (Lok et al., 1988). 
Isolated HBsAb positivity, which usually indicates prior vaccination or resolved infection, is 
not generally considered a risk for HBV transmission. Historically, prospective organ 
donors with either HBsAg or HBcAb positivity were not utilized because of the significant 
risk of HBV transmission to a liver transplant recipient. However, it has now become more  
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common to transplant livers from HBcAb+ or HBsAg-positive donors with intensive 
posttransplantation prophylaxis (Dodson et al., 1999; Wachs et al., 1995).  
The relative risk of HBV transmission and posttransplantation management based on the 
serologic test results of the donor is summarized in Table 5. A donor who is positive for 
HBsAg poses the greatest risk of HBV transmission after transplantation. The risk of HBV 
infection may be reduced in recipients who are positive for anti-HB antibodies; however, 
infection has been well documented after transplantation from a donor positive for HBsAg, 
irrespective of the recipient's immunization status. Therefore, all recipients receiving 
transplanted organs from HBsAg-positive donors should be prophylactically treated with 
hepatitis B immunoglobulin (HBIG) and antiviral therapy. The major drawback of HBIG 
therapy is the cost, and, therefore, diverse strategies of HBIG administration, in terms of 
dosage and duration, exist in different transplantation centers. However, frequent 
monitoring of liver function, HBsAg, anti-HB antibodies, and HBV DNA in the allograft 
recipient, as well as the maintenance of adequate anti-HB antibody levels, is recommended.  
Antibodies against the HBcAg are only present after HBV infection, and they cannot be the 
result of previous HBV vaccination. Therefore, organs from any donor testing positive for 
anti-HBc antibodies can transmit HBV to allograft recipients. A positive result for anti-HBc 
antibodies should be further defined by determining whether the antibodies are of the IgM 
or the IgG class in order to identify donors with either recent HBV exposure or current HBV 
infection. If the anti-HBc antibody is of the IgM class, indicating a recent or ongoing acute 
HBV infection, then recipients should be treated in a manner analogous to allograft 
recipients from an HBsAg-positive donor. If the anti-HBc antibody is of the IgG class, then 
there is high risk of HBV transmission with liver transplantation. The approach to liver 
transplantation from an anti-HBc IgG-positive donor should be as aggressive as that from 
an HBsAg-positive donor. Therefore, the same regimens of HBIG in combination with oral 
lamivudine are recommended. However, several centers have described the successful 
prevention of graft HBV using lamivudine therapy alone (Malkan et al., 2000; Mutimer et 
al., 2000). Additionally, HBsAg, anti-HB antibody levels, and HBV DNA should be closely 
monitored in recipients in order to detect active infection as well (Chung et al., 2001). 
 
Donor HBV serology Risk of HBV transmission Post-transplantation Prophylaxis 
HBsAg + High HBIG and lamivudine 
Anti-HBc IgM +, 
HBsAg -, 
Anti-HBs +/- 
High HBIG and lamivudine 
Anti-HBc IgG +, 
HBsAg -, 
Anti-HBs +/- 
High HBIG and lamivudine 
or lamivudine alone 
HBsAg -, 
Anti-HBc -, 
Anti-HBs +/- 
Rare Not recommended 
HBsAg, hepatitis B Surface antigen; Anti-HBc, antibody of hepatitis B core antigen; Anti-
HBs, antibody of hepatitis B surface antigen; HBIG, hepatitis B immunoglobulin.  
Table 5. Relative risk of HBV transmission and suggested post-transplantation management 
of liver transplant recipients according to donor serologic status 
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The lowest risk of HBV transmission occurs when the donor is negative for both HBsAg and 
anti-HBc antibodies, a situation that is considered evidence of no active infection. However, 
in rare cases, HBV transmission to liver allograft recipients has been reported, even when 
the donors are negative for all markers of HBV, including HBsAg, anti-HBc antibodies, and 
anti-HB antibodies (Chazouilleres et al., 1994) 
4.5.4 Hepatitis C virus  
Prospective organ donors with HCV infection have traditionally posed a dilemma because 
of the high risk of transmission of HCV through organ transplantation. A donor positive for 
HCV RNA, indicating active viral replication, has a much higher risk of transmission 
(Pereira et al., 1992). The risks of transmission from HCV RNA-negative and HCV antibody-
positive donors have not yet been fully defined. However, all recipients of organs from 
HCV-infected donors are indeed at risk of becoming HCV infected after liver 
transplantation. In recent years, the use of organs from HCV-seropositive donors for life-
saving transplantations in HCV-seronegative recipients has been studied, with acceptable 
results. There are no increases in the 1- and 5-year mortality and morbidity rates associated 
with liver transplantation from HCV-positive versus HCV-negative donors (Rosengard et 
al., 2002).  
The greatest concern of HCV infection after liver transplantation is that at least 25% of 
recipients progress to cirrhosis within 5 years, with a 42% annual risk of decompensation 
once cirrhosis has developed (Berenguer, 2002). The treatment of HCV in liver transplant 
recipients is complicated further by poor sustained viral response (SVR) rates and reports of 
progressive fibrosis with hepatic decompensation despite SVR. Combination therapy for 
HCV after liver transplantation is currently recommended, and the most widely used is 
pegylated-interferon (Peg-IFN) plus ribavirin. Treatment of HCV with Peg-IFN plus 
ribavirin after liver transplantation is generally only successful in achieving SVR in 20–45% 
of recipients and is associated with high rates (30–50%) of discontinuation due to 
intolerability (Ponziani et al., 2011; Wang et al., 2006). The inability to reach target RBV 
doses due to the high prevalence of renal insufficiency in recipients is a major limiting factor 
in achieving an acceptable SVR rate (Chalasani et al., 2005; Gane et al., 1998).  
In contrast to HBV, there is no HCV vaccine to prevent transmission. A general concept in 
managing liver transplant recipients at risk for HCV infection or recurrence is to avoid 
precipitating factors, such as acute rejection, the use of older or extended criteria donors, 
and CMV infection. Additionally, slow tapering of all immunosuppressive agents and 
avoiding over- or under-immunosuppression is theoretically more likely to lead to a lower 
incidence of HCV recurrence and acute rejection. 
4.5.5 Human immunodeficiency virus (HIV) 
HIV-seropositive donors have traditionally not been utilized in transplantation, due to the 
known risk of transmission to the recipient. However, despite routine screening, 
transmission of HIV, which can be an uncommon complication of organ transplantation, is a 
public health concern. Specifically, if the donor is in the window period after infection but 
prior to development of anti-HIV antibodies, the recipient is at risk of HIV infection (Ahn & 
Cohen, 2008).  
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The CDC guidelines address donor screening, testing, and exclusion for prevention of HIV 
transmission through organ transplantation. The guidelines note that prospective donors 
may be considered if “the risk to the recipient of not performing the transplant is deemed to 
be greater than the risk of HIV transmission and disease.” In this circumstance, informed 
consent is deemed essential. Posttransplant testing of all recipients of high-risk donors for 
HIV is suggested but not mandated. The treatment of recipients infected by donor-derived 
HIV transmission is similar to that of HIV-seropositive individuals who have undergone 
liver transplantation after HIV infection has been confirmed. To maintain virological control 
of HIV infection, it is recommended to regularly and quantitatively measure HIV RNA and 
CD4-positive T-cell counts. If patients have persistent HIV viremia, a phenotypic HIV drug 
resistance assay should be carried out to determine alternative treatment options (Blumberg 
& Stock, 2009).  
4.5.6 Other unusual viruses 
Respiratory viruses, including influenza, respiratory syncytial virus, parainfluenza virus, 
rhinovirus, human metapneumovirus, coronavirus, bocavirus, and polyomaviruses, have 
been identified as causes of significant morbidity and mortality among transplant recipients. 
All of these viruses cause a range of diseases, from mild congestion and rhinorrhea, to more 
severe tracheobronchitis, bronchiolitis, and pneumonia. Transplant recipients are at a higher 
risk of infectious complications than are immunocompetent hosts, and they often present 
with mild or atypical symptoms. Although respiratory viruses are increasingly recognized 
in transplant recipients, there is still much to be learned about their impact. Prospective 
studies are needed to define the optimal timing, duration, and treatment regimen of each of 
the viruses.  
Parvovirus B19, which is a nonenveloped single-stranded DNA virus, is a common human 
pathogen that causes erythema infectiosum in children. The virus is primarily spread 
person-to-person by infected respiratory droplets, but transmission through organ 
transplantation has been reported as well (Yango et al., 2002). Parvovirus B19 infection can 
be either symptomatic or asymptomatic, depending on the age and immunologic status of 
the host. In immunocompromised hosts, this infection can cause persistent anemia and 
occasionally pancytopenia. Therefore, parvovirus B19 infection should be specifically 
suspected in solid organ transplant recipients with otherwise unexplained anemia. 
Currently, there is no antiviral drug available for the treatment of parvovirus infection, but 
intravenous immunoglobulin has been shown to be beneficial in transplant recipients with 
parvovirus B19 infection (Eid et al., 2006). 
Adenovirus is an important viral infection in pediatric liver transplantation. The clinical 
presentations of infected patients range from self-limited fever, gastroenteritis, or cystitis, to 
devastating illness with necrotizing hepatitis or pneumonia. Symptomatic infections 
frequently occur early after transplantation, indicating the possibility of donor transmission 
(Ison, 2006). The diagnoses of adenovirus can be performed through antigen detection, 
culture, molecular diagnosis, or histopathology. Unfortunately, there is no definitive 
treatment for adenoviral infection at this time. The most important component of 
therapeutic strategy is supportive care along with a reduction of the degree of 
immunosuppression (Ison & Green, 2009). 
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Human T-lymphotropic virus (HTLV-I/II), which is endemic in certain areas including the 
Caribbean and Japan, is often asymptomatic. Infection with HTLV-I can progress to HTLV-I-
associated myelopathy/tropical spastic paraparesis or adult T-cell leukemia/lymphoma 
after years or decades. Serology for HTLV-I/II is routinely performed in the US but not in 
other areas. In Europe and other areas, this assay is restricted to donors living in, or 
originating from, high-incidence areas. HTLV-I-seropositive donors are often not utilized 
and are only considered in life-threatening situations with appropriate informed consent. 
However, the use of HTLV-I-seropositive donors should be conducted with caution because 
the donor-derived transmission of HTLV-I with rapid development of myelopathy in 
recipients has been reported (Toro et al., 2003). 
West Nile virus (WNV), a flavivirus that can cause meningoencephalitis has recently 
appeared in the United States. WNV transmission through blood transfusions and solid 
organ transplantation has been reported as well (Iwamoto et al., 2003). Organ recipients 
receiving immunosuppressive drugs may be at high risk for severe disease after WNV 
infection. The US Health Resources and Service Administration has issued a guidance 
statement regarding donors and WNV, which recommends testing all prospective live 
donors with nucleic acid amplification tests (NAAT) prior to transplant and suggests 
avoiding the use of organs from donors with any form of unexplained or confirmed WNV 
encephalitis.  
Lymphocytic choriomeningitis virus (LCMV), a rodent-associated arenavirus, has been 
reported with donor-derived transmission to organ recipients leading to fatal infection 
(Fischer et al., 2006). LCMV infection in humans with normal immune systems usually 
causes either asymptomatic or mild, self-limited illnesses. Aseptic meningitis can occur in 
some patients, but the infection is rarely fatal. However, LCMV can cause serious infection 
in persons with impaired immune systems. 
Rabies, a rhabdovirus, is another potentially fatal donor-derived infection (Srinivasan et al., 
2005). The virus spreads inward from nerve endings in muscle or skin to the CNS and then 
disseminates outward to other organs. The majority of infected individuals develop the 
furious or encephalitic form of the disease, while others develop the paralytic or dumb form, 
mimicking Guillain-Barre syndrome. The disease is highly lethal, leading to very few 
survivors following infection (Willoughby et al., 2005). Therefore, clinicians are encouraged 
to avoid donors who pose even a small risk of rabies infection. 
5. Transmission of malignancy 
Malignancy after transplantation can develop in three different ways: (1) de novo 
occurrence, (2) recurrence of malignancy, and (3) donor-related malignancy that can be due 
to either direct transmission of tumors or tumors arising in cells of donor origin. Despite all 
efforts to secure a safe organ for transplantation, there continues to be some risk of donor-
derived malignancy that can be transmitted to recipients (Ison et al., 2009). Such risks may 
specifically be overlooked in the emergent donation process. Therefore, the risk of 
unintended transmission of tumors from donors to recipients must be placed in perspective. 
Few reports on transmitted cancers have been published, and the risk has never been 
reliably quantified. One study quantified the risk using a population-based cancer registry, 
and they estimated a 1.3% risk of having a donor with an undetected malignancy and a 0.2% 
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risk of cancer transmission (Birkeland & Storm, 2002). These risks are small compared with 
the benefits of organ transplantation. 
Melanoma is one of the most frequently reported and lethal donor-derived malignancies 
with a high transmission rate (Strauss & Thomas, 2010). The transmission of melanoma 
might be related to the biological characteristics of melanoma, including tumor dormancy, 
late recurrence, circulating tumor cells, and the destiny of micrometastases. Melanoma cell 
dormancy explains the late recurrence that can occur long after the initial treatment of 
melanoma. The high incidence of circulating tumor cells should be considered in the context 
of melanoma transmission, even in organ donors with early melanoma who present 
apparently disease-free following removal of a primary melanoma up to several decades 
previously. This scenario suggests that melanoma cells can remain dormant at distant sites 
for decades and possibly forever in immunocompetent patients and reactivate only after 
transplantation into an immunosuppressed recipient. Therefore, prospective organ donors 
should be carefully screened for a history of melanoma. The current recommendation for the 
treatment of donor-related melanoma in renal transplant recipients includes withdrawal or 
discontinuation of immunosuppression leading to graft rejection, followed by explantation 
of the allograft after rejection (Penn, 1996). However, this approach is certainly not feasible 
for liver transplant recipients because of the lack of alternative organ support.  
Additionally, prospective organ donors with a past history of several malignancies, 
including choriocarcinoma, lung cancer, and advanced-stage breast or renal cancer, should 
be avoided, despite curative resections. Donors with an extended disease-free interval after 
curative breast, colon, or renal surgery may be used after a detailed review of pathology 
reports. The use of organs from donors with small, localized, low-grade renal cell carcinoma 
is acceptable, as demonstrated by the fact that kidneys with such locally excised tumors 
have been transplanted without evidence of malignancy transmission. Moreover, organs 
from donors with in situ cancers can be considered with minimal hesitation and with the 
recipient’s informed consent. Donors with cerebral malignancies rarely transmit these 
tumors to recipients. The risk of malignancy transmission utilizing organs from donors with 
benign or low-grade astrocytoma (grade I and II) is extremely low. In contrast, the use of 
organs from donors with high-grade astrocytoma (grade III-IV) tumors, malignant tumors 
with ventriculosystemic shunts, or histories of extensive cranial surgery that disrupts the 
blood-brain barrier, is associated with a higher donor malignancy transmission rate (Buell et 
al., 2003). 
Once a donor-transmitted malignancy is suspected, confirmation is essential in order to 
determine treatment approach. Confirmation can be made by the comparison of donor and 
recipient tumor histology, fluorescence in-situ hybridization (FISH), which has been utilized 
to identify the donor origin of tumor cells in sex-mismatched transplant recipients, or PCR-
based amplification of highly polymorphic regions in the DNA. Recent reports have relied 
upon FISH and PCR analysis to confirm tumor origins (Gandhi & Strong, 2007). The fact 
that tumors in transplant recipients arise from foreign DNA can be exploited. However, 
there is currently no consensus in the guidelines for the management of recipients with 
donor-transmitted malignancies. In some cases, the reduction or cessation of 
immunosuppression might lead to rejection of the donor-derived tumor, which is perceived 
as a foreign antigen by the recovering immune system of the recipients, similar to the 
rejection of a transplanted organ by a nonimmunosuppressed recipient. However, a 
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majority of the recipients also require a traditional approach to treating the malignancy, 
including specific antineoplastic chemotherapy, radiotherapy, or surgery.  
6. Conclusion 
Donor-derived disease transmission remains a rarely recognized complication of solid organ 
transplantation, although the reported number of potential donor-derived infections and 
malignancies has increased every year. This increase is most likely the result of the 
improved recognition and the development of a formalized reporting process. The true 
incidence rates are not well known but will be clarified over time through enhanced 
reporting systems and the improved evaluation of suspicious cases. Since there is 
substantial morbidity and mortality among affected recipients, a better understanding of the 
risk of disease transmission is important in order to better inform patients and to provide 
advice on how to minimize transmissions in the future.  
Additionally, thorough pretransplantation screening of the donor and recipient for potential 
diseases is essential to the success of transplantation as well as to determine prophylactic 
and preventive strategies to be utilized after transplantation. Future advances will likely 
include more rapid diagnostic testing to refine the assessment of the risks of transmission 
posed by a particular donor. Moreover, clinicians should be constantly aware of the possibility 
of the donor-derived transmission of diseases. Earlier identification of transmission events 
may decrease morbidity and mortality rates through earlier intervention. 
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